Compare Abeona Therapeutics Inc (ABEO) vs Carnival Corp (CCL) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Carnival Corp — how do they compare? Abeona Therapeutics Inc trades at $6.73 (market cap $373.32M), while Carnival Corp trades at $25.54 (market cap $36.54B). The key difference: Carnival Corp is far larger — about 97.9× Abeona Therapeutics Inc's market cap, and Carnival Corp pays a 1.12% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | CCL | |
|---|---|---|
Market Cap | $373.32M | $36.54B |
Sector | Health | Consumer Cyclical |
52-Week High | $7.23 | $33.99 |
52-Week Low | $4.17 | $23.89 |
Enterprise Value | $228.22M | $60.47B |
Dividend Yield | — | 1.12% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Carnival Corporation (CCL) trades at $26.68, down 4.41% on the day, with a bearish technical signal despite recent earnings beats. The company shows strong fundamental recovery with revenue growing to $26.62B in 2025 and net income reaching $2.76B. Positive analyst sentiment exists with a $35.45 consensus price target, though near-term headwinds in European demand and cost pressures are noted.
The outlook for CCL is cautiously optimistic. Strong booking trends and debt reduction support long-term growth, but investors face risks from geopolitical issues, fuel costs, and competitive pressures. The stock presents potential upside from current levels if execution continues, but requires monitoring of guidance and macroeconomic factors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Carnival Corp
Carnival is the largest global cruise company, with 91 ships in its fleet in October 2022, with eight of its nine brands set to be fully redeployed by the end of 2022. Its portfolio of brands includes Carnival Cruise Lines, Holland America, Princess Cruises, and Seabourn in North America.
Read more on CCL →
